SCHEMBL22100175

SCHEMBL22100175

COc1ccccc1C(=O)CC(CC(=O)c1ccccc1OC)c1cc(O)c(O)c(O)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 2/20 0.52
TDO2 P48775 2/20 0.52
L3MBTL1 Q9Y468 4/20 0.50
ALDH1A1 P00352 3/20 0.50
HTT P42858 2/20 0.50
KMT2A Q03164 2/20 0.50
NPC1 O15118 2/20 0.48
POLB P06746 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
CTSD P07339 1/20 0.44
CTNNB1 P35222 1/20 0.43
WNT3A P56704 1/20 0.43
HDAC8 Q9BY41 1/20 0.43
HDAC1 Q13547 1/20 0.43
MAPT P10636 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
KCNMA1 Q12791 1/20 0.42
TTR P02766 1/20 0.42
MEN1 O00255 1/20 0.42
GAA P10253 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22133149 0.86 IDO1 (0.41) IDO1TDO2L3MBTL1ALDH1A1HTT
SCHEMBL22074296 0.83 L3MBTL1 (0.51) IDO1TDO2L3MBTL1ALDH1A1HTT
SCHEMBL29500531 0.83 L3MBTL1 (0.51) IDO1TDO2L3MBTL1ALDH1A1HTT
SCHEMBL29500535 0.80 L3MBTL1 (0.67) IDO1TDO2L3MBTL1ALDH1A1HTT
SCHEMBL22074273 0.80 L3MBTL1 (0.67) IDO1TDO2L3MBTL1ALDH1A1HTT
SCHEMBL22074268 0.78 NPC1 (0.43) IDO1TDO2L3MBTL1ALDH1A1HTT
SCHEMBL29500532 0.77 L3MBTL1 (0.48) IDO1TDO2L3MBTL1ALDH1A1HTT
SCHEMBL22074243 0.77 L3MBTL1 (0.48) IDO1TDO2L3MBTL1ALDH1A1HTT
SCHEMBL13647205 0.76 NPC1 (0.58) IDO1TDO2L3MBTL1ALDH1A1HTT
SCHEMBL25712016 0.73 CTSD (0.56) IDO1TDO2L3MBTL1ALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11208371-B2 Compounds, compositions, and methods for use in treating autophagy-associated disorders BIOPHAGY INC (US) 2021-12-28 US disclosed
WO-2020131924-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR USE IN TREATING AUTOPHAGY-ASSOCIATED DISORDERS Biophagy, Inc. (US) 2020-06-25 WO disclosed
US-20200190007-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR USE IN TREATING AUTOPHAGY-ASSOCIATED DISORDERS BIOPHAGY INC (US) 2020-06-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200190007-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR USE IN TREATING AUTOPHAGY-ASSOCIATED DISORDERS BECN1, ATG7, SQSTM1 IDO1 3130/4885TDO2 4148/4885L3MBTL1 2229/4885
US-11208371-B2 Compounds, compositions, and methods for use in treating autophagy-associated disorders BECN1, ATG7, SQSTM1 IDO1 3130/4885TDO2 4148/4885L3MBTL1 2229/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.